Adiporon Agonist for Diabetic Osteoporosis via AdipoR1/2 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic and postmenopausal osteoporosis either fail to restore bone mass or lead to fatal complications, and existing therapies do not effectively address the increased risk of fractures associated with these conditions.
Innovation Solution
A pharmaceutical composition containing adiporon, which selectively acts on adiponectin-receptor 1/2, activating AMPK and PPARα signaling pathways to improve hyperglycemia, dyslipidemia, and bone metabolism, thereby reducing inflammation, oxidative stress, and promoting bone growth and density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing treatments (bisphosphonates, growth hormones, calcitonin) are used for diabetic and postmenopausal osteoporosis, then bone density may be maintained or slightly improved, but fracture risk remains high and severe side effects occur
Solution Approach 1:
The patent uses adiporon as an intermediary substance that activates adiponectin receptors (AdipoR1 and AdipoR2) to mediate the protective effects against osteoporosis. Adiporon serves as a mediator between metabolic regulation and bone protection, activating AMPK and PPARα signaling pathways to improve bone quality without the severe side effects of conventional treatments
Solution Approach 2:
The patent changes the therapeutic parameter from simply increasing bone density to improving bone quality through metabolic regulation. By targeting adiponectin receptors and activating AMPK/PPARα pathways, the treatment shifts focus from quantitative bone mass accumulation to qualitative bone strength improvement, addressing the underlying metabolic abnormalities in diabetic osteoporosis
2Quantity of substance
If PPAR-γ ligand oral antidiabetic drugs are used, then diabetes control is improved, but bone metabolism is negatively affected and fracture risk increases
Solution Approach 1:
Instead of using PPAR-γ ligands that harm bone metabolism, the patent inverts the approach by using PPARα agonists (adiporon) that protect bone. This inverse strategy targets a different PPAR isoform (α instead of γ) to achieve metabolic control while providing bone protection, reversing the harmful effect on bone metabolism
3Quantity of substance
If incretin therapy (GLP-1, GIP, DPP-4 inhibitors) is used, then diabetes control is improved and bone mass is maintained, but fracture risk increases
Solution Approach 1:
The patent copies the beneficial bone-protective effect of adiponectin through its synthetic agonist adiporon, rather than using incretin therapy. By replicating adiponectin's mechanism of action on AdipoR1/AdipoR2 receptors, the treatment achieves bone protection through a different pathway that does not increase fracture risk despite maintaining bone mass
Data Source
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating diabetic and postmenopausal osteoporosis comprising adiporon and/or a method for treating diabetic and postmenopausal osteoporosis using the same. The composition of the present invention controls bone-related factors by activating the adiponectin-receptor 1-AMPK-Nrf2 signaling system and the adiponectin-receptor 2/PPARα-PGC-1α signaling system in bone tissue, improves lipotoxicity and can be usefully used as a therapeutic agent for diabetic and postmenopausal osteoporosis through growth plate promoting effects and chondrocyte proliferation effects in growth plates.